AACR 2021 roundup
Evaluate Vantage's coverage of the virtual AACR 2021 congress.
In advance of AACR, Evaluate Vantage's Jacob Plieth spoke to the biotech investor Brad Loncar about the meeting's themes.
Also check out our coverage of AACR 2021.
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
Phase 1 results at this weekend’s virtual AACR show an unexpected win for Affimed’s AFM13 and a disappointing update from Oncternal.
The company might finally become an oncology player.
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.